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Summary Background Ipilimumab is an antibody that targets
the cytotoxic T-lymphocyte antigen-4 to potentiate an antitumor
response. Adding ipilimumab 10mg/kg to paclitaxel (PTX) and
carboplatin (CBDCA) in a phased schedule improved
progression-free survival in a phase II non-small-cell lung can-
cer (NSCLC) study. Methods This dose-escalating, phase I
study was designed to identify the recommended dose of
ipilimumab (3 or 10mg/kg) by evaluating dose-limiting toxicity
(DLT; Cycles 3 and 4) in phased combination with PTX
(175 mg/m2) and CBDCA (area under the curve=6) in
Japanese patients with advanced NSCLC. Treatment was ad-
ministered intravenously every 3 weeks initially, followed by
some eligible patients receiving maintenance ipilimumab once
every 12 weeks. Additional endpoints included safety, tumor
response, pharmacokinetics, and immunogenicity. Results
Fifteen patients were enrolled and 12 received ipilimumab
(n=6, 3 mg/kg; n=6, 10 mg/kg) in combination with PTX
andCBDCA.DLTs occurred in 2 patients (ipilimumab 3mg/kg)
and 1 patient (ipilimumab 10 mg/kg). The most common grade
3/4 adverse events (AEs) were decreased hemoglobin, leukope-
nia, and neutropenia. The most common immune-related AEs
affected the skin, gastrointestinal, and nervous system. The safe-
ty profile was similar in both cohorts. Three patients in each
cohort achieved a partial response. The pharmacokinetic (PK)
profile of ipilimumab in Japanese patients was similar to that
observed in previous studies in non-Japanese patients.
Conclusions The recommended dose of ipilimumab in phased
combination with PTX and CBDCA in Japanese patients with
NSCLC was identified as 10 mg/kg. The safety profile was
consistent with the previously defined AE profile.
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Introduction
Patients with newly diagnosed non-small-cell lung cancer
(NSCLC) typically present with locally advanced stage III or
metastatic stage IV disease. Platinum-based chemotherapy com-
binations, the current standard of care for this patient population,
offer responses of between 30 and 60 %, but survival benefit is
limited (median overall survival of approximately 9 months),
and new treatment options are needed [1]. One of the most
promising developments in the search for novel treatments has
been the advent of immune-checkpoint inhibitors that harness
the power of the patient’s own immune system to fight cancer
[2]. Ipilimumab is a fully human, monoclonal antibody that
targets the immune-checkpoint cytotoxic T-lymphocyte anti-
gen-4 (CTLA-4) to potentiate T-cell-mediated antitumor re-
sponse [3]. Ipilimumab is approved as either first- or second-
line therapy in over 40 countries for the treatment of
unresectable or metastatic melanoma, but is not currently ap-
proved in Japan [4, 5]. The potential use of ipilimumab in the
treatment of other tumor types is an area of intense investigation.
Recently, ipilimumab 10 mg/kg in combination with pacli-
taxel (PTX) and carboplatin (CBDCA) was evaluated in
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patients with previously untreated, advanced NSCLC in a ran-
domized, multicenter, double blind, phase II study [6]. In this
study, patients received ipilimumab in a phased or concurrent
regimen. Patients treated with the phased regimen received
two doses of placebo plus PTX/CBDCA, followed by four
doses of ipilimumab plus PTX/CBDCA; those treated with
the concurrent regimen received four doses of ipilimumab
plus PTX/CBDCA, followed by two doses of placebo plus
PTX/CBDCA. Treatment was administered intravenously ev-
ery 3 weeks for ≤18 weeks (induction). Eligible patients con-
tinued ipilimumab or placebo every 12 weeks as maintenance
therapy. The addition of ipilimumab to PTX/CBDCA in a
phased schedule significantly increased progression-free sur-
vival (PFS) compared with PTX/CBDCA alone. No statisti-
cally significant difference was observed between concurrent
ipilimumab and PTX/CBDCA versus PTX/CBDCA alone.
Ipilimumab in combination with PTX/CBDCAwas well tol-
erated. Taken together, these results suggest that ipilimumab
in combination with PTX/CBDCA on a phased schedule was
safe and active in this patient population.
The primary objective of this open-label, dose-escalation,
phase I s tudy (CA184-113 , Cl in ica lTr ia l s .gov :
NCT01165216) was to establish the recommended dose of
ipilimumab in a phased combination regimen with PTX/
CBDCA in Japanese patients with advanced or metastatic
NSCLC. Safety, tumor response, pharmacokinetics, and im-
munogenicity were also assessed.
Methods
Patients
Japanese patients of either sex were eligible to participate in
this study if they had histologically- or cytologically-
documented stage IIIB NSCLC and were not candidates for
definitive thoracic radiotherapy, stage IVNSCLC, or recurrent
disease following radiotherapy and/or surgery. Eligible pa-
tients were required to have adequate bone marrow function
(hemoglobin≥9.0 g/dL, absolute neutrophil count [ANC]≥
1500/mm3, and platelet count≥100,000/mm3), liver function
(total bilirubin≤2.0 times the upper limit of normal [x ULN],
aspartate aminotransferase [AST]≤2.5 × ULN, alanine ami-
notransferase [ALT]≤2.5 × ULN), and renal function (calcu-
lated creatinine clearance based on Cockcroft and Gault for-
mula≥50 mL/min). Other inclusion criteria included age of at
least 20 years; no prior chemotherapy, hormonal therapy, im-
munotherapy or targeted therapy for NSCLC; a life expectan-
cy of at least 3 months; an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1; and the ability
and willingness to comply with visits and procedures as spec-
ified in the protocol (patients were admitted to the hospital
from at least Day 1 to Day 22 of the third treatment cycle).
Patients were ineligible to participate in this study if they
had symptomatic brain metastases or brain metastases requir-
ing medication, a history of autoimmune disease or motor
neuropathy of autoimmune origin, peripheral neuropathy of
grade 2 or higher, diarrhea of grade 2 or higher, current or a
history of gastrointestinal perforations, and chronic use of im-
munosuppressants and/or systemic corticosteroids.
Study oversight
This study was sponsored by Bristol-Myers K.K. All proce-
dures performed in studies involving human participants were
in accordance with the ethical standards of the institutional
and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable
ethical standards. The study protocol was approved by the
Institutional Review Board and research was conducted in
accordance with the standards specified by Article 14
Paragraph 3 and Article 80-2 of the Pharmaceutical Affairs
Law, and Good Clinical Practice, as defined by the
Ministerial Ordinance Concerning the Standards for the
Implementation of Clinical Studies on Pharmaceutical
Products and concerning notifications. All study participants
provided written informed consent prior to enrollment.
Study design and treatment
In this open-label, dose-escalation, phase I study, patients with
advanced or metastatic NSCLC were treated with ipilimumab
(3 or 10 mg/kg) in combination with PTX (175 mg/m2) and
CBDCA (area under the curve [AUC]=6). The treatment
schedule was divided into two treatment periods (Fig. 1).
During the first treatment period, patients received phased
ipilimumab, which consisted of two cycles of PTX/CBDCA
every 3 weeks (q3wks) followed by four cycles of ipilimumab
plus PTX/CBDCA q3wks. During the second treatment peri-
od, patients without disease progression received ipilimumab
alone once every 12 weeks (q12wks) as maintenance treat-
ment. To be eligible for maintenance treatment, patients were
required to meet core safety criteria and have adequate bone
marrow function (ANC>1500/mm3 and platelet count>100,
Fig. 1 Schema for study CA184-113. C, paclitaxel/carboplatin; DLT,
dose-limiting toxicity; IPI, ipilimumab; Tx, treatment; q3wks, every
3 weeks; q12wks, every 12 weeks
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000/mm3). Patients were enrolled in successive cohorts of 3 to
6 patients using a standard ‘3+3’ design. The recommended
dose was defined as the highest dose at which not more
than 2 out of 6 patients experienced a dose-limiting
toxicity (DLT), taking into consideration the profile of
DLTs and the frequency and severity of toxicities after
the DLT evaluation period. The final recommended dose
was agreed upon by the Sponsor and principal investigator.
Patients received ipilimumab at 3 mg/kg (Cohort A) or
10 mg/kg (Cohort B).
Study endpoints and assessments
The primary objective of this study was to identify the recom-
mended dose of ipilimumab in a phased combination regimen
with PTX/CBDCA in Japanese patients with advanced or
metastatic NSCLC. The recommended dose was defined as
the highest dose at which not more than 2 out of 6 patients had
DLT during the first two cycles after ipilimumab treatment
(i.e., from Day 1 at Cycle 3 to Day 21 at Cycle 4). Dose-
limiting toxicities included any of the following: grade 4
ANC decrease lasting for 7 days or more; febrile neutropenia
lasting more than 3 days; grade 4 platelet count decrease;
grade 3 platelet count decrease requiring transfusion; grade 3
or higher nausea, vomiting, and/or diarrhea despite the use of
adequate/maximal medical intervention; grade 3 or higher
AST/ALT levels not resolved to grade 2 or less within 2 weeks
of onset; grade 3 or higher rash not resolved to grade 2 or less
within 2 weeks of onset; and any grade 3 or higher non-
hematological toxicity (except grade 3 fatigue, grade 3 asthe-
nia, grade 3 transient arthralgia/myalgia, and grade 3 transient
abnormal electrolyte).
Secondary objectives were safety and tolerability, tumor
response, and pharmacokinetics (PK) of ipilimumab. Safety
and tolerability was defined as the incidence of AEs occurring
throughout the study period. These assessments were based on
the National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI-CTCAE) version 3.0 [7]. Tumor
response was defined as the best overall response rate
(BORR). Responses were based on Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1 [8]. Blood
serum samples for assessing PK of ipilimumab were drawn
at the following time points: Cycle 3 (Day 1, 2, 3, 8, and 15),
Cycle 4 (Day 1), Cycle 5 (Day 1), Cycle 6 (Day 1), Week 24
and subsequent cycles, and off treatment. Quantification of
ipilimumab in serumwas performed using a validated enzyme
linked immunosorbent assay (ELISA). Ipilimumab PKs were
derived from serum concentration-versus-time data.
Pharmacokinetic parameters included peak plasma concentra-
tion (Cmax), area under the concentration-versus-time curve
from time zero to Day 21 (AUC0-21d), time of maximum ob-
served serum concentration (Tmax), serum half-life (T-HALF),
clearance (CL), and volume of distribution at steady-state
(Vss). Geometric mean and coefficient of variation were cal-
culated for Cmax, AUC0-21d, CL, and Vss. Mean and standard
deviation were calculated for T-HALF.Median, minimum and
maximum were calculated for Tmax.
Immunogenicity was evaluated as an exploratory end-
point. Blood samples were evaluated for the presence of
antibodies to ipilimumab (human anti-human antibodies
[HAHA]). Blood samples were drawn pre-dose on Day
1 of the third cycle and prior to each subsequent dose
of ipilimumab, off treatment, and at first follow-up in case of
discontinuation before Week 24. The detection of HAHAwas
performed using a validated bridging electrochemiluminescence
immunoassay, which provided a semi-quantitative as-




Fifteen patients with advanced or metastatic NSCLC were
enrolled and treated at the National Cancer Center Hospital
in Tokyo, Japan between September 2010 and June 2013;
patient characteristics at baseline are provided in Table 1.
Eight patients were enrolled in Cohort A (ipilimumab
3 mg/kg), and 7 patients were enrolled in Cohort B
(ipilimumab 10 mg/kg). Six patients in each study cohort re-
ceived ipilimumab treatment. Three patients were
Table 1 Patient characteristics






Number of ipilimumab-treated patients 6 6 12
Sex, n (%)
Male 6 (75.0) 6 (85.7) 12 (80.0)
Female 2 (25.0) 1 (14.3) 3 (20.0)
Age, years
Median 61.5 61.0 61.0
Range 27–65 40–70 27–70
Disease status, n (%)
Stage IV 6 (75.0) 5 (71.4) 11 (73.3)
Recurrent 2 (25.0) 2 (28.6) 4 (26.7)
Tumor type, n (%)
Adenocarcinoma 8 (100.0) 6 (85.7) 14 (93.3)
Squamous cell carcinoma 0 (0.0) 1 (14.3) 1 (6.7)
Ipi ipilimumab
a Including patients who were discontinued before receiving ipilimumab
due to intolerable toxicity associated with chemotherapy (n=2, Cohort A)
and withdrawal of informed consent (n=1, Cohort B)
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discontinued prior to receiving ipilimumab. The reasons for
discontinuation were intolerable toxicity (n=2, Cohort A) and
withdrawal of informed consent (n=1, Cohort B). The median
age was similar in the two dose cohorts and the majority of
patients were male with stage IV disease. All patients had
adenocarcinoma, with the exception of one patient in Cohort
B who had squamous cell carcinoma.
Treatment and dosing information is provided in Table 2.
The majority of patients required a dose delay of study drug
(n=11/12, ipilimumab; n=12/15, PTX/CBDCA). Two pa-
tients in Cohort A (ipilimumab 3 mg/kg) and one patient in
Cohort B (ipilimumab 10 mg/kg) required a chemotherapy
dose reduction, which occurred during the fifth or sixth treat-
ment cycle. One patient in Cohort B received a maintenance
dose of ipilimumab, and all patients were off treatment at the
end of the study. For the total study population, the reasons for
study discontinuation (n=15) were study drug toxicity (60 %),
disease progression (26.7 %), and discontinuation at the pa-
tient’s request (13.3%). In Cohort A (ipilimumab 3mg/kg, n=
8), 6 patients discontinued due to study drug toxicity (75 %), 1
patient discontinued due to disease progression (12.5 %), and
1 patient requested to discontinue (12.5 %). In Cohort B
(ipilimumab 10 mg/kg, n=7), 3 patients discontinued due to
study drug toxicity (42.9 %), 3 patients discontinued due to
disease progression (42.9 %), and 1 patient requested to dis-
continue (14.3 %).
Safety data
In Cohort A (ipilimumab 3 mg/kg), DLT was reported
in 2 of 6 patients. One patient experienced grade 3
febrile neutropenia and grade 4 increased amylase after
4 doses of chemotherapy and 2 doses of ipilimumab.
The febrile neutropenia resolved after treatment with
granulocyte colony-stimulating factor (G-CSF) and anti-
biotics; the increased amylase required no treatment.
Another patient experienced grade 4 thrombocytopenia
after 4 doses of chemotherapy and 2 doses of
ipilimumab. The thrombocytopenia resolved after a
platelet transfusion. In Cohort B (ipilimumab 10 mg/kg),
DLT was reported in 1 of 6 patients. This patient expe-
rienced grade 3 enterocolitis, grade 3 increased total
bilirubin, and grade 4 increased lipase after 4 doses of
chemotherapy and two doses of ipilimumab. The entero-
colitis and increased total bilirubin resolved with treatment,
which included a high-dose steroid (prednisone),
levofloxacin, meropenem, and parenteral nutrition; and the
increase lipase resolved without treatment.
A summary of treatment-related adverse events (AEs)
in patients who received PTX/CBDCA and at least one
dose of ipilimumab is shown in Table 3. The most com-
mon grade 3/4 AEs (occurring in 3 or more patients)
were neutropenia (n=6, Cohort A; n=6, Cohort B), de-
creased hemoglobin (n=4, Cohort B), and leukopenia
(n=3, Cohort A; n=1, Cohort B). The most frequent
lower-grade (1/2) AEs that occurred in greater than
20 % of patients in either cohort included decreased ap-
petite (n=4, cohort A; n=5, cohort B), arthralgia (n=3,
cohort A, n=5, cohort B), rash (n=5, cohort A; n=3, cohort
B), nausea (n=4, cohort A; n=3, cohort B), prolonged QT
(n=4, cohort A; n=2, cohort B), fatigue (n=2, cohort A;
n=4, cohort B), and peripheral sensory neuropathy (n=1, co-
hort A; n=5, cohort B).
Table 4 provides a summary of immune-related adverse
events (irAEs) in patients who received PTX/CBDCA and at
least one dose of ipilimumab. The most commonly reported
irAEs across the two study cohorts were grade 1/2 toxicities
affecting the skin and subcutaneous tissues (n=5, Cohort A;
n=6, Cohort B), gastrointestinal tract (n=4, Cohort A; n=1,
Cohort B), and nervous system (n=3, Cohort A; n=5, Cohort
B). Two patients in Cohort A experienced a grade 3/4 irAE
(n=1, grade 3 adrenal insufficiency; n=1, grade 4 increase in
amylase). The grade 3 adrenal insufficiency occurred on Day
159, after 6 cycles of chemotherapy and 4 doses of
ipilimumab. It was treated with oral prednisolone that was
continued through to the last follow-up assessment due to
unresolved decreases in both adrenocorticotropic hormone
and cortisol. The grade 4 increase in amylase required no
treatment. Two patients in Cohort B experienced a grade 3/4
irAE (n=1, grade 3 enterocolitis, grade 3 increase in blood
Table 2 Treatment and number of doses that patients received
Cohort A Cohort B Total
(N=15)(n=8) (n=7)




Number of doses, n
Ipilimumab
0 2 (25.0) 1 (14.3) 3 (20.0)
1 0 (0) 0 (0) 0 (0)
2 3 (37.5) 1 (14.3) 4 (26.7)
3 0 (0) 2 (28.6) 2 (13.3)
4 3 (37.5) 2 (28.6) 5 (33.3)
5 (maintenance dose) 0 (0) 1 (14.3) 1 (6.7)
6 (maintenance dose) 0 (0) 0 (0) 0 (0)
Paclitaxel/carboplatin
0 0 (0) 0 (0) 0 (0)
1 2 (25.0) 0 (0) 2 (13.3)
2 0 (0) 1 (14.3) 1 (6.7)
3 0 (0) 0 (0) 0 (0)
4 3 (37.5) 1 (14.3) 4 (26.7)
5 0 (0) 4 (57.1) 4 (26.7)
6 3 (37.5) 1 (14.3) 4 (26.7)
Ipi ipilimumab
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Table 3 Summary of treatment-related adverse events in patients who received PTX/CBDCA and at least one dose of ipilimumab
Toxicitiesa,b Cohort A Cohort B
(n=6) (n=6)
Ipi 3 mg/kg Ipi 10 mg/kg
Total (G1-4) G3 G4 Total (G1-4) G3 G4
Hematological, n (%)
Hemoglobin decreased 0 (0) 0 (0) 0 (0) 4 (66.7) 4 (66.7) 0 (0)
Leukopenia 3 (50.0) 3 (50.0) 0 (0) 1 (16.7) 1 (16.7) 0 (0)
Lymphopenia 1 (16.7) 0 (0) 1 (16.7) 0 (0) 0 (0) 0 (0)
Neutropenia 6 (100.0) 0 (0) 6 (100.0) 6 (100.0) 3 (50.0) 3 (50.0)
Febrile neutropenia 1 (16.7) 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0)
Thrombocytopenia 1 (16.7) 0 (0) 1 (16.7) 2 (33.3) 0 (0) 0 (0)
Gastrointestinal, n (%)
Nausea 4 (66.7) 0 (0) 0 (0) 3 (50.0) 0 (0) 0 (0)
Diarrhea 3 (50.0) 0 (0) 0 (0) 1 (16.7) 0 (0) 0 (0)
Constipation 2 (33.3) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0)
Vomiting 1 (16.7) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0)
Enterocolitis 0 (0) 0 (0) 0 (0) 1 (16.7) 1 (16.7) 0 (0)
Metabolism and nutrition disorders, n (%)
Decreased appetite 4 (66.7) 0 (0) 0 (0) 5 (83.3) 0 (0) 0 (0)
Hypocalcaemia 1 (16.7) 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0)
Hypomagnesaemia 1 (16.7) 0 (0) 1 (16.7) 0 (0) 0 (0) 0 (0)
Dermatologic, n (%)
Rash 5 (83.3) 0 (0) 0 (0) 3 (50.0) 0 (0) 0 (0)
Alopecia 1 (16.7) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0)
Dry skin 1 (16.7) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0)
Pruritus 0 (0) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0)
Mediastinal disorders, n (%)
Hiccups 0 (0) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0)
Oropharyngeal pain 2 (33.3) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0)
Musculoskeletal and connective tissue disorders, n (%)
Arthralgia 3 (50.0) 0 (0) 0 (0) 5 (83.3) 0 (0) 0 (0)
Peripheral sensory neuropathy 1 (16.7) 0 (0) 0 (0) 5 (83.3) 0 (0) 0 (0)
Other, n (%)
Blood sodium decreased 0 (0) 0 (0) 0 (0) 1 (16.7) 1 (16.7) 0 (0)
GGT increased 0 (0) 0 (0) 0 (0) 1 (16.7) 1 (16.7) 0 (0)
Hyponatremia 1 (16.7) 1 (16.7) 0 (0) 1 (16.7) 1 (16.7) 0 (0)
Hypophosphatemia 0 (0) 0 (0) 0 (0) 1 (16.7) 1 (16.7) 0 (0)
Lipase increased 0 (0) 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (16.7)
Amylase increased 1 (16.7) 0 (0) 1 (16.7) 1 (16.7) 0 (0) 0 (0)
Blood bilirubin increased 0 (0) 0 (0) 0 (0) 1 (16.7) 1 (16.7) 0 (0)
Adrenal insufficiency 1 (16.7) 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0)
Prolonged QT 4 (66.7) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0)
Weight decrease 3 (50.0) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0)
Dysgeusia 2 (33.3) 0 (0) 0 (0) 1 (16.7) 0 (0) 0 (0)
Hypoesthesia 2 (33.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Fatigue 2 (33.3) 0 (0) 0 (0) 4 (66.7) 0 (0) 0 (0)
Pyrexia 1 (16.7) 0 (0) 0 (0) 3 (50.0) 0 (0) 0 (0)
G grade, GGT gamma-glutamyltransferase, ipi ipilimumab
aOnly toxicities that reached Grade 3/4 in severity or occurred in >20 % of patients in either cohort are presented
bAssessment based on National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0
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bilirubin, and grade 4 increase in lipase; n=1, grade 3 increase
in gamma-glutamyltransferase [GGT]). The grade 3 enteroco-
litis resolved with treatment with a high-dose steroid, and the
grade 3 increase in blood bilirubin was treated with agents
including oral prednisolone, levofloxacin, and meropenem,
and parenteral nutrition. The grade 4 increase in lipase and
grade 3 increase in GGT both resolved without treatment.
One patient in Cohort B experienced an irAE of grade
2 pneumonitis on Day 126 after receiving 5 cycles of
chemotherapy and 3 doses of ipilimumab. The pneumonitis
resolved following treatment with intravenous methylprednis-
olone and then oral prednisolone which was gradually
tapered.
Efficacy data
Efficacy was assessed in patients who received at least
one dose of study medication (N=15). In Cohort A
(3 mg/kg, n=8), 3 patients achieved a partial response
(PR) and an additional 3 patients achieved stable disease
(SD). Two patients were not evaluable because they
discontinued prior to the first tumor assessment due to
chemotherapy toxicity. In Cohort B (10 mg/kg, n=7), 3
patients achieved a PR and an additional 4 patients
achieved SD. One patient who achieved SD requested
to discontinue prior to the first dose of ipilimumab
10 mg/kg.
Table 4 Immune-related adverse events in patients who received PTX/CBDCA and at least one dose of ipilimumab
Toxicitiesa Cohort A Cohort B
(n=6) (n=6)
Ipi 3 mg/kg Ipi 10 mg/kg
G1/2 G3/4 Total G1/2 G3/4 Total
Skin and subcutaneous tissue disorders 5 (83.3) 0 (0) 5 (83.3) 6 (100.0) 0 (0) 6 (100.0)
Rash 5 (83.3) 0 (0) 5 (83.3) 3 (50.0) 0 (0) 3 (50.0)
Alopecia 1 (16.7) 0 (0) 1 (16.7) 2 (33.3) 0 (0) 2 (33.3)
Pruritus 0 (0) 0 (0) 0 (0) 2 (33.3) 0 (0) 2 (33.3)
Pigmentation disorder 1 (16.7) 0 (0) 1 (16.7) 0 (0) 0 (0) 0 (0)
Dermatitis acneiform 0 (0) 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (16.7)
Rash maculo-papular 0 (0) 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (16.7)
Gastrointestinal disorders 4 (66.7) 0 (0) 4 (66.7) 1 (16.7) 1 (16.7) 2 (33.3)
Diarrhea 3 (50.0) 0 (0) 3 (50.0) 1 (16.7) 0 (0) 1 (16.7)
Gastritis 1 (16.7) 0 (0) 1 (16.7) 0 (0) 0 (0) 0 (0)
Stomatitis 1 (16.7) 0 (0) 1 (16.7) 1 (16.7) 0 (0) 1 (16.7)
Enterocolitis 0 (0) 0 (0) 0 (0) 0 (0) 1 (16.7) 1 (16.7)
Nervous system disorders 3 (50.0) 0 (0) 3 (50.0) 5 (83.3) 0 (0) 5 (83.3)
Hypoesthesia 2 (33.3) 0 (0) 2 (33.3) 0 (0) 0 (0) 0 (0)
Peripheral motor neuropathy 1 (16.7) 0 (0) 1 (16.7) 0 (0) 0 (0) 0 (0)
Peripheral sensory neuropathy 1 (16.7) 0 (0) 1 (16.7) 5 (83.3) 0 (0) 5 (83.3)
Endocrine disorders 1 (16.7) 1 (16.7) 2 (33.3) 0 (0) 0 (0) 0 (0)
Adrenal insufficiency 0 (0) 1 (16.7) 1 (16.7) 0 (0) 0 (0) 0 (0)
Hypoparathyroidism 1 (16.7) 0 (0) 1 (16.7) 0 (0) 0 (0) 0 (0)
Laboratory investigations 0 (0) 1 (16.7) 1 (16.7) 1 (16.7) 2 (33.3) 3 (50.0)
Amylase increased 0 (0) 1 (16.7) 1 (16.7) 1 (16.7) 0 (0) 1 (16.7)
Blood bilirubin increased 0 (0) 0 (0) 0 (0) 0 (0) 1 (16.7) 1 (16.7)
Blood corticotrophin decreased 0 (0) 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (16.7)
Blood cortisol decreased 0 (0) 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (16.7)
Blood TSH decreased 0 (0) 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (16.7)
GGT increased 0 (0) 0 (0) 0 (0) 0 (0) 1 (16.7) 1 (16.7)
Lipase increased 0 (0) 0 (0) 0 (0) 0 (0) 1 (16.7) 1 (16.7)
Respiratory, thoracic and mediastinal disorders 0 (0) 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (16.7)
Pneumonitis 0 (0) 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (16.7)
G grade, GGT gamma-glutamyltransferase, ipi ipilimumab, TSH thyroid-stimulating hormone
aAssessment based on National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0
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Pharmacokinetic data
Table 5 provides summary statistics for ipilimumab PK pa-
rameters during Cycle 3 and PK data from non-Japanese pa-
tients treated with ipilimumab in previous clinical studies [9,
10]. Serum ipilimumab levels were elevated with median
values of Tmax from 2.75 to 3.98 h. The observed mean T-
HALF of ipilimumab was approximately 11 to 13 days. The
geometric mean CL was 12.0 to 14.4 mL/h, and Vss was
approximately 5 L. The PK profile in this study was similar
to that reported in previous clinical trials of non-Japanese pa-
tients [9, 10]. The concentration of serum ipilimumab over
time is shown in Fig. 2.
Immunogenicity
A total of 61 samples from the 12 ipilimumab-treated patients
were evaluated for the presence of HAHA to ipilimumab; all
samples were negative for HAHA.
Discussion
In this phase I study in Japanese patients with advanced
NSCLC using the definition defined in the protocol, and
agreed upon by the sponsor and Pl, the recommended dose
was identified as 10 mg/kg of ipilimumab in a phased combi-
nation with PTX/CBDCA. This dosage of ipilimumab is be-
ing studied in two on-going phase III lung cancer studies:
CA184-104 (CT.gov, NCT01285609) and CA184-156
(CT.gov, NCT01450761) [11, 12].
Overall, the safety profile was consistent with data from
previous studies of ipilimumab in combination with PTX/
CBDCA [6] and known toxicities of ipilimumabmonotherapy
[13] and PTX and CBDCA [14]. Two out of 6 patients treated
with ipilimumab 3 mg/kg experienced DLTs with 3 events
reported: grade 3 febrile neutropenia, grade 4 increased amy-
lase, and grade 4 thrombocytopenia. The increased amylase
required no treatment. Transient febrile neutropenia and
thrombocytopenia are common chemotherapy-related AEs


















Japanese patients (current study)
Cohort A Ipi 3 mg/kg (n=6) 72.8 (12) 12,632 (12) 2.75 (1.37–4.08) 13.3 (3.64) 12 (17) 4.97 (17)
Cohort B Ipi 10 mg/kg (n=6) 201 (21) 36,489 (21) 3.98 (1.45–23.8) 11.3 (2.83) 14.4 (25) 5.35 (22)
Non-Japanese patients (historical data)
Ipi 3 mg/kg (N=12)a 84.5 12,384 N/A 15.25 N/A N/A
Ipi 10 mg/kg (N=14)b 234.54 (29) 46925.36 (36) 1.51 (1.5-24.0) 13.93 (7.54) 11.63 (50) 5.10 (25)
AUC area under the concentration-versus-time curve, CL clearance, Cmax peak plasma concentration, CV coefficient of variation, ipi ipilimumab, N/A
data not available, SD standard deviation, T-HALF time required to decrease the drug concentration in the blood by half, Vss volume of distribution at
steady-state
a Data from non-Japanese melanoma patients treated with hybridoma-derived ipilimumab 3 mg/kg monotherapy in study MDX010-15 [9]
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Fig. 2 Ipilimumab serum
concentration profile versus time
during Cycle 3. Open circles,
ipilimumab 3 mg/kg plus
PTX/CBDCA group (n=6);
closed circles, ipilimumab
10 mg/kg plus PTX/CBDCA
group (n=6). Data are mean plus
standard deviation. On Day 1 of
Cycle 3, blood serum samples
were drawn at the following time
points: Pre-infusion, 1.5 h
(just prior to the end of
ipilimumab dosing), 4 h and 24 h
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[14]. One of 6 patients treated with ipilimumab 10 mg/kg had
DLT with 3 events reported: grade 3 enterocolitis, grade 3
increased total bilirubin, and grade 4 increased lipase.
Enterocolitis is a common irAE associated with ipilimumab
[13]. Increased bilirubin has been described as associated with
ipilimumab [13] and chemotherapy [15], and increased lipase
is commonly experienced as a chemotherapy-related AE [16]
as well. In both dose cohorts, the majority of AEs were hema-
tological, although non-hematological toxicities were also re-
ported (Table 3). There was no clear association between the
incidence of AEs and the dose of ipilimumab, as reported in
prior studies [17].Most common safety events associated with
ipilimumab are inflammatory in nature, which may reflect its
immune-based mechanism of action [18]. The most common
irAEs across the two study cohorts were grade 1/2 toxicities
affecting the skin, gastrointestinal tract, and nervous system.
Immune-related toxicities were manageable with established
treatment guidelines [13].
Although conclusions regarding efficacy in phase I studies
are necessarily limited, ipilimumab in a phased combination
with PTX and CBDCA demonstrated encouraging prelimi-
nary antitumor activity. Among the 12 evaluable patients
who received at least one dose of ipilimumab, 3 patients in
each cohort achieved a partial response, and an additional 3
patients in each cohort achieved stable disease. Stable disease
is a potentially clinically relevant outcome with ipilimumab
treatment because some patients experience a slow and steady
decrease in total tumor burden following a period of SD [19,
20]. Antitumor activity was demonstrated also in the phase II
CA184-041 study [6]. Among patients who received phased
ipilimumab in combination with PTX and CBDCA (n=68) in
study CA184-041, 22 achieved an immune-related partial re-
sponse and 37 had an immune-related SD, as assessed by a
blinded independent radiologic review committee [6, 20].
The PK profile of ipilimumab at two doses, 3 mg/kg and
10 mg/kg, was also evaluated in the current study. Data from
previous studies have shown no major PK interactions between
ipilimumab administered at 10 mg/kg in Caucasians and PTX/
CBDCA [10]. Acknowledging the limitations of comparing
data from different studies, the PK characteristics of ipilimumab
observed in the current study were similar to those previously
reported in clinical trials of non-Japanese patients [9, 10].
Although ipilimumab is a fully human antibody, it has the
potential to induce formation of anti-drug antibodies when it is
administered as a therapeutic agent [21]. None of the
ipilimumab-treated patients in this study had HAHA, and
therefore there was no evidence of an anti-ipilimumab anti-
body response.
In summary, the recommended dose for ipilimumab in
combination with PTX/CBDCA in Japanese patients with
NSCLC was identified as 10 mg/kg. The first 2 treatment
cycles in this study were PTX/CBDCA every 3 weeks and
the last 4 treatment cycles were ipilimumab plus PTX/
CBDCA every 3 weeks. The safety profile of ipilimumab in
combination with PTX and CBDCA was consistent with the
previously defined profile established in global clinical stud-
ies. Overall, the PK characteristics of ipilimumab in combina-
tion with PTX and CBDCAwere similar to those demonstrat-
ed in global clinical studies in non-Japanese subjects.
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